Description:
Dapagliflozin, an SGLT2 inhibitor, is a guideline-directed therapy for heart failure with reduced ejection fraction (HFrEF) and is also approved for heart failure with preserved ejection fraction (HFpEF), regardless of diabetes status. It improves symptoms, reduces hospitalizations, and lowers cardiovascular mortality. Though more expensive than generics, it's often covered by insurance and considered cost-effective due to its clinical benefits.
Treatment For:
AI generated Summary: Based on the single review provided, Dapagliflozin appears to be a highly effective first-line treatment for Congestive Heart Failure. It is recommended alongside standard therapies to reduce hospitalizations and cardiovascular death, despite being more expensive than generic alternatives.
Dapagliflozin is a first-line treatment for heart failure, recommended alongside standard therapies to reduce hospitalizations and cardiovascular death. It is brand-name only and more expensive than generics, but typically covered by insurance due to its proven benefits.
The information, including but not limited to, text, graphics, images and other material contained on this website/app are for informational purposes only. No material on this site/app is intended to be a substitute for professional medical advice, diagnosis or treatment. Always seek the advice of your physician or other qualified healthcare provider with any questions you may have regarding a medical condition or treatment and before undertaking a new health care regimen, and never disregard professional medical advice or delay in seeking it because of something you have read on this website/app.
Copyright © 2025,Curbside and related marks are registered trademarks of Curbside Tech Inc.
